STTR Phase I: Development of Ultrathin Nanomembranes for Home-based Hemodialysis

STTR 第一阶段：开发用于家庭血液透析的超薄纳米膜

• 批准号: 1521373
• 负责人: James Roussie
• 金额: $ 22.5万
• 依托单位: SiMPore, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1521373&HistoricalAwards=false
• 关键词: STTR; Phase; Development; Ultrathin; Nanomembranes

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project relates to the treatment of end-stage renal disease, a significant health burden in the US. Trends are moving toward patient-managed, in-home treatments. The goal of this proposal is to accelerate adoption of safer home hemodialysis therapy through development of prototype dialysis systems. Despite the recognized economic, health and quality-of-life benefits of more frequent hemodialysis treatments, adoption of home hemodialysis using present systems is being limited by doctors? and patients? safety concerns. Simpler and safer hemodialysis therapies will require breakthroughs in both device components and form-factors. The development of a small-scale, highly efficient dialysis system enabled by silicon nanomembranes holds potential for increasing adoption of home dialysis and its related benefits for the 430,000 individuals affected by end-stage renal disease in the US.The proposed project concerns the scale up of silicon nanomembranes, which offer extraordinary and unparalleled permeability, enabling small-scale hemodialysis. This project focuses on the optimization of membrane ?liftoff?methods which enable the release of large areas of silicon nanomembranes from silicon wafer supports on which they are produced, thereby simultaneously increasing active membrane area and reducing production cost. Fluidic housings will be developed for these membranes appropriate for blood volumes for large animal (Pig/sheep) and human scales. Bench-top validation will be conducted to measure toxin clearance and ultrafiltration in the prototype system.

该小企业技术转让（STTR）I期项目的更广泛影响/商业潜力与终末期肾病的治疗有关，这是美国的一个重大健康负担。趋势正在转向患者管理的家庭治疗。本提案的目标是通过开发原型透析系统加速采用更安全的家庭血液透析治疗。尽管更频繁的血液透析治疗具有公认的经济、健康和生活质量益处，但使用现有系统的家庭血液透析的采用受到医生的限制？和病人？安全问题。更简单、更安全的血液透析治疗需要在设备组件和外形尺寸方面取得突破。由硅纳米膜实现的小规模高效透析系统的开发具有增加家庭透析的采用及其对美国430，000名受终末期肾病影响的个体的相关益处的潜力。拟议的项目涉及硅纳米膜的规模扩大，其提供非凡和无与伦比的渗透性，使小规模血液透析成为可能。本课题主要研究膜分离技术的优化。升空？本发明涉及能够从其上生产硅纳米膜的硅晶片载体释放大面积硅纳米膜的方法，从而同时增加活性膜面积并降低生产成本。将为这些膜开发适用于大型动物（猪/羊）和人类规模的血量的流体外壳。将进行实验室验证，以测量原型系统中的毒素清除和超滤。